SINGAPORE — Invitrocue and Angsana Molecular & Diagnostics Laboratory have announced a strategic partnership with Averywell to introduce a next-generation, miRNA-based liquid biopsy for early lung cancer detection.
The collaboration integrates advanced molecular diagnostics with existing LDCT workflows. By improving the risk stratification of lung nodules, the partnership aims to support more informed clinical decision-making for patients across Singapore and the broader Asia region.
Read the full press release here.